Clinical trial NCT00120419: Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: HIV Infection
Keywords: HIV-1 infection
immunomodulatory therapy
Treatment Naive
Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sponsor class: OTHER
Collaborators: name: Hoffmann-La Roche
name: Sanquin Research & Blood Bank Divisions
First posted: 2005-07-18
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of the study is to evaluate whether mycophenolate mofetil (MMF) can treat the chronic hyperactivation of the immune system and (partly) prevent the decrease of the CD4+ T-cell count in chronically HIV-1 infected patients who are not treated with antiretroviral therapy (ART). The researchers also want to know what the effect is of treatment with MMF on plasma HIV-1 RNA; progression of disease (occurrence of AIDS defining events or reaching the indication to start ART); and the safety of treatment with MMF in this patient group.

Detailed description: \*Background: During chronic HIV-1 infection the immune system is chronically hyperactivated. This hyperactivation is considered as the main cause of CD4+ T-cell loss. Furthermore, HIV replicates most efficiently in activated CD4+ T-cells. In this study we try to inhibit the activation of the immune system with mycophenolate mofetil (MMF). Previous studies in which HIV-1 infected patients have been treated with MMF in addition to antiretroviral treatment (ART) have not shown any additional effect, compared to ART alone. In this study MMF will be used without antiretroviral medication.

\*Objectives: Primary objective of the study is the evaluation of the effect of MMF on the chronic hyperactivation of the immune system and the decrease of the CD4+ T-cell count in chronically HIV-1 infected patients who are not treated with antiretroviral therapy (ART). Secondary objectives include the evaluation of the effect of MMF on plasma HIV-1 RNA; progression of disease/ reaching of indication to start ART; and the safety of treatment with MMF in this patient group.

\*Study Design: This is a multi center, randomized, open-label study, in which patients will be randomized to treatment with mycophenolate mofetil (MMF) 500 mg BID during 48 weeks versus no treatment. In a subgroup of 20 patients ("immunology group", the first 20 patients in the AMC hospital, Amsterdam, the Netherlands) a number of additional immunological measurements will be performed.

The study duration is 60 weeks (48 weeks of treatments with 1 additional visit 12 weeks after cessation of treatment).

\*Study Population: Potential participants are adult chronically HIV-1 infected patients, who have never been treated with ART and who according to the present criteria do not need to be treated. CD4+ T lymphocyte count has to be \> 250 and \<= 450 \* 106/L, plasma HIV-1 RNA (viral load) \< 10.000 copies/ mL.

\*Intervention: Patients will be randomized (1:1) to mycofenolate mofetil (MMF) 500 mg BID versus no treatment.

\*Endpoints: Primary endpoints are change over time (baseline - week 48) in CD4+ T cell count and peripheral blood lymphocyte (PBMC) activation markers.

Secondary endpoints are changes over time (baseline - week 48) in plasma HIV-1 RNA, time to reach indication to start ART (separated in three groups: 1. two consecutive measurements of CD4+ T cell count below 250 \* 106 cells/ L with at least 4 weeks interval; 2. the occurrence of a CDC class B or C event; 3. any other reason); safety data.

Eligibility criteria: Inclusion Criteria:

* Patient is ≥ 18 years of age;
* Patient has a proven HIV-1 infection (with antibodies against HIV-1 and a detectable plasma HIV-1 RNA measured for the first time at least 6 months prior to inclusion);
* Patient is HIV-1 treatment naïve;
* CD4+ T lymphocyte count \> 250 and \<= 450 \* 106/L;
* No signs or history of AIDS defining events;
* No use of other medications that might possibly influence the effects of MMF;
* Male; or female sex and willingness to practice effective contraception during the study.

Exclusion Criteria:

* Plasma HIV-1 RNA \< 10.000 copies/ mL;
* Autoimmune disease;
* Active hepatitis B or C virus infection;
* Other chronic diseases;
* Recent infectious disease other than HIV-1;
* Treatment with immunomodulatory or anti-inflammatory medication in the past 6 months;
* For female patients: pregnancy and lactation;
* Any other condition, illness or use of medication which according to the investigator is not compatible with the use of the study medication or which could interfere with the evaluations required by the study.

Primary outcomes:
measure: Change over time (baseline - week 48) in CD4+ cell counts in peripheral blood and peripheral blood lymphocyte activation markers.
Secondary outcomes:
measure: * Change over time (baseline - week 48) in plasma HIV-1 RNA, time to reach an indication to start antiretroviral treatment and safety parameters.
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: OLVG
state: NH
city: Amsterdam
country: Netherlands
facility: Academic Medical Center
state: NH
city: Haarlem
country: Netherlands
facility: Kennemer Gasthuis, location EG
state: NH
city: Rotterdam
country: Netherlands
facility: Erasmus Medical Center
state: ZH
city: The Hague
country: Netherlands
facility: HAGA hospital, location Leyenburg Hospital
state: ZH
Study officials:
affiliation: Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, the Netherlands
name: Jan M Prins, MD PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: department of internal medicine, OLVG hospital, Amsterdam, the Netherlands
name: Kees Brinkman, MD PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: department of internal medicine, Kennemer Gasthuis, Haarlem, the Netherlands
name: Robin Soetekouw, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Internal Medicine, HAGA hospital, location Leyenburg Hospital, The Hague, The Netherlands
name: Robert Kauffmann, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chapuis AG, Paolo Rizzardi G, D'Agostino C, Attinger A, Knabenhans C, Fleury S, Acha-Orbea H, Pantaleo G. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med. 2000 Jul;6(7):762-8. doi: 10.1038/77489.
citation: Sankatsing SU, Jurriaans S, van Swieten P, van Leth F, Cornelissen M, Miedema F, Lange JM, Schuitemaker H, Prins JM. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS. 2004 Sep 24;18(14):1925-31. doi: 10.1097/00002030-200409240-00008.
citation: Garcia F, Plana M, Arnedo M, Brunet M, Castro P, Gil C, Vidal E, Millan O, Lopez A, Martorell J, Fumero E, Miro JM, Alcami J, Pumarola T, Gallart T, Gatell JM. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study. J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):823-30. doi: 10.1097/00126334-200407010-00009.